BioWorld

July 10, 2002

View Archived Issues

Santarus Partners Technology With TAP In Potential $100M Deal

Santarus Inc. stands to gain up to $100 million through a licensing agreement announced Tuesday with TAP Pharmaceutical Products Inc. aimed at developing a next-generation therapy for upper gastrointestinal diseases. (BioWorld Today) Read More

Elan Seeking US$1B In Asset Sale As Top Executive Departs

Read More

Staphylococcus aureus Finally Outlasted Vancomycin, But New Antibiotics Are Treating Patient

Read More

Micrologix Signs MBI 226 Deal With Fujisawa For Up To $21M

Read More

Other News To Note

Read More

AIDS Conference

Read More